The document discusses validation of processing techniques for wet granulation. It outlines key parameters that must be considered and validated at each stage of wet granulation including blending, wet granulation, drying, and tablet compression. Parameters like mixing time and speed, binder concentration, granulation endpoint, drying temperature and moisture content, and compression force must be optimized and shown to consistently produce tablets meeting quality standards. Equipment used at each stage must also be validated to ensure it is suitable for the processing steps.
Autoclave
Principle of Autoclave
Construction of Autoclave
Working of Autoclave
Qualification of Autoclave
Installation Qualification
Operational Qualification
Performance Qualification
References
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Autoclave
Principle of Autoclave
Construction of Autoclave
Working of Autoclave
Qualification of Autoclave
Installation Qualification
Operational Qualification
Performance Qualification
References
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Aseptic / sterile- “ A state of control attained by using an aseptic work area and performing activities in a manner that precludes microbiological contamination of the exposed sterile product”
Qualification of tablet compression machinePritam Kolge
Qualification of Tablet Compression Machine ...
This topic comes under Quality Control and Quality Assurance....
This is useful for M.Pharm (Pharaceutical Quality Assurance) Students who studying in First year sem II....
This Presentation Contain following...
#Introduction
#Design Qualification
#Installation Qualification
#Operational Qualification
#Performance Qualification
#Case Study
#Conclusion
#References
Thanks For Help and Guidance of Dr. Mrs. N. M. Bhatia Mam
Ipqc tests for sterile formulations are as follows :
Leakage Test
Clarity Test
pH
Particulate Matter Injection
SterilityTest
Pyrogen Test
Content Uniformity & Weight
Volume Filled
The tests For Sterile products are as per IP, BP & USP
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
Aseptic / sterile- “ A state of control attained by using an aseptic work area and performing activities in a manner that precludes microbiological contamination of the exposed sterile product”
Qualification of tablet compression machinePritam Kolge
Qualification of Tablet Compression Machine ...
This topic comes under Quality Control and Quality Assurance....
This is useful for M.Pharm (Pharaceutical Quality Assurance) Students who studying in First year sem II....
This Presentation Contain following...
#Introduction
#Design Qualification
#Installation Qualification
#Operational Qualification
#Performance Qualification
#Case Study
#Conclusion
#References
Thanks For Help and Guidance of Dr. Mrs. N. M. Bhatia Mam
Ipqc tests for sterile formulations are as follows :
Leakage Test
Clarity Test
pH
Particulate Matter Injection
SterilityTest
Pyrogen Test
Content Uniformity & Weight
Volume Filled
The tests For Sterile products are as per IP, BP & USP
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
The Validation Master Plan is a a valuable opportunity to provide an overview of your company’s validation process, including organization structure, content, and planning.
Process Validation is Key important factor for the Pharmaceutical Industry to maintain Consistent Quality in product which claimed by the manufacturer.
Raw material validation- process validationRavish Yadav
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Pilot plant scale-up is a branch of the pharma companies in which a lab-scale formula is converted into a commercially viable product by creating a reliable manufacturing technique. The same techniques employed in dosage form Research and Development are adapted to multiple output volumes, frequently larger than those obtained during Research and Development. There is always a requirement for an intermediate batch scale describing techniques and imitating those in commercial manufacturing in any new or established pharmaceutical sector. This is accomplished by testing the formula’s ability to survive batch-scale and process changes.
Similar to Validation of processing techniques (20)
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
This pdf is about the Schizophrenia.
For more details visit on YouTube; @SELF-EXPLANATORY;
https://www.youtube.com/channel/UCAiarMZDNhe1A3Rnpr_WkzA/videos
Thanks...!
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
The ambient solar wind that flls the heliosphere originates from multiple
sources in the solar corona and is highly structured. It is often described
as high-speed, relatively homogeneous, plasma streams from coronal
holes and slow-speed, highly variable, streams whose source regions are
under debate. A key goal of ESA/NASA’s Solar Orbiter mission is to identify
solar wind sources and understand what drives the complexity seen in the
heliosphere. By combining magnetic feld modelling and spectroscopic
techniques with high-resolution observations and measurements, we show
that the solar wind variability detected in situ by Solar Orbiter in March
2022 is driven by spatio-temporal changes in the magnetic connectivity to
multiple sources in the solar atmosphere. The magnetic feld footpoints
connected to the spacecraft moved from the boundaries of a coronal hole
to one active region (12961) and then across to another region (12957). This
is refected in the in situ measurements, which show the transition from fast
to highly Alfvénic then to slow solar wind that is disrupted by the arrival of
a coronal mass ejection. Our results describe solar wind variability at 0.5 au
but are applicable to near-Earth observatories.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...Scintica Instrumentation
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes.
In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
4. 1. Mixing or Blending ensures production of uniform
mixture of active pharmaceutical ingredients and
excipients that do not segregate post blending. So this
step is carefully scrutinized and validated.
• Parameters to consider:
Mixing or blending technique
Mixing or blending speed
Mixing or blending time:
Drug uniformity
Excipient uniformity
Equipment capacity/load .
5. 1. Mixing or Blending - Material have similar physical properties
will be easier to form a uniform mix or blend as compare to
difference in properties.
2. Techniques-
1- diffusion(tumble)
2- convection(planetary or high intensity or fluid bed.
Mixing or blending depending on various factor-
(a)Mixing speed - mixing the drug & excipient will require more
intense mixing than adding the lubricant to the final blend.
(b)Mixing time - mixing time will be dependent on the mixing
technique & speed.
6. • If over mixed occured at the result demixing or segregation
of the material.
(c)Drug uniformity - handling of the material is key in
obtaining valid content uniformity results .
• Segregation of the sample can occur by handling resulting
inaccurate results.
• Sample should be equivalent to the weight of a single tablet.
(d)Excipient uniformity - excipient need to be uniform in the
granulation. Two keys excipient are-
(A)-LUBRICANT- lubricant needs to be distributed uniformly
in the mixture/granulation for high speed compression
operation
7. Uneven distribution of the lubricant can result in picking &
sticking problem during compresion.
(B)Color-evenly distributed in the mixture so the tablets have
a uniform appreance (color,hue & intensity)
• Uniform dispersed in the blend prior to compression to avoid
shading(molting).
(e)Equipment capacity/load-the bulk density of material will
affect the capacity of the equipment . • Undercharging or
overcharging a blender can result in poor drug or tablet lubricant
distribution.
8. 2. Wet Granulation : Wet granulation parameters to be
considered during development and validation are:
Binder addition
Binder concentration
Amount of binder solution/granulating solvent
Binder solution/granulating solvent addition
Mixing time
Granulation end point
9. Wet granulation parameters to be considered during
development and validation are:
Binder concentration and addition: The optimal binder
concentration will need to be determined for the formulation. If
the binder is to be sprayed, the binder solution needs to be
diluted enough so that it can be pumped through the nozzle. It
should also be sufficiently concentrated to form granules
without overwetting the materials.
Amount of binder solution: how much binder or solvent solution
is required to granulate the materials?. Too much binder or
solvent solution will over wet the materials and prolong the
drying time.
10. Binder solution addition rate: Define the rate at which the
binder solution can be added to the material.
Mixing time: How long the material should be mixed to ensure
proper formation of granules. Over mixing the granulation can
lead to harder granules and a lower dissolution rate.
Granulation end point: How is the granulation end point
determined? Is it controlled by specifying critical processing
parameters?.
•EQUIPMENT VALIDATION:
•MIXER/GRANULATOR:
• a. What is the method of mixing (e.g., planetary, pneumatic)?
11. • b. Is the equipment capable of providing low and/or high
shear to the material?
•c. Can the mixing be varied (e.g., changing the rpm of the
impeller)?
• d. Does the mixer/granulator have a monitoring system (e.g.,
end point detection) or can it accommodate one?
e. What is the working load range and capacity of the
equipment? f. How is material charged and discharged from the
unit? Is it manual, semi-automated, or automated? g. Are there
options to introduce the granulating fluid (e.g., dump, meter, or
spray)?
12. 3. Drying
The type of drying technique (e.g., tray, fluid bed, and microwave)
required for the formulation needs to be determined and justified.
The type of technique may be dependent on such factors as drug
or formulation properties and equipment availability.
Changing dryer techniques could affect such tablet properties as
hardness, disintegration, dissolution, and stability.
The optimal moisture content of the dried granulation needs to be
determined. High moisture content can result in tablet picking or
sticking to tablet punch surfaces and poor chemical stability as a
result of hydrolysis.
13. An over dried granulation could result in poor hardness and
friability. Moisture content analysis can he performed using the
conventional loss-on-drying techniques or such state-of-the-art
techniques as near infrared (NIR) spectroscopy.
Factors to be considered are:
1. Inlet/outlet temperature
2. Airflow
3. Moisture uniformity
4. Equipment capability/capacity
14. (A) Inlet/outlet temp.
• Inlet temp.should be set high enough to maximinise drying
without affecting the physical/chemical stability.
• The outlet temp. is an indicator of the granulation temp. &
insufficient air flow could prolong drying will increase toward
the inlet temp.as the moisture content of the granulation
decreases (evaporization rate).
(B) Air flow & moisture content could vary within the
granulation
• Drying also affect the moisture in the granulation.
15. •EQUIPMENT EVALUATION
• DRYER
• a. What is the operating principle of the dryer (e.g., direct
heating—fluid bed, indirect conduction—tray, or indirect
radiant—microwave)?
• b. Will the wet material be static (e.g., tray) or fluid (e.g., fluid
bed)?
• c. What is the working load range and capacity of the
equipment?
• d. What is the heating range and airflow capabilities of the
equipment?
•
16. •e. What is the heat distribution of the unit? Are there any hot
and/ or cold spots?
• f. Can the unit pull a vacuum? What is the vacuum range of
the unit?
• g. Can the equipment handle different types of filter bags? For
example, can a filter bag be dedicated to a particular product?
17. 4. Tablet Compression
Compression is a critical step in the production of a tablet dosage
form. The materials being compressed will need to have adequate
flow and compression properties. The material should readily flow
from the hopper onto the feed frame and into the dies.
Inadequate flow can result in “rat holing” in the hopper and/or
segregation of the blend in the hopper/feed frame.
This can cause tablet weight and content uniformity problems.
Factors to consider during compression are as follows:
Tooling
Compression speed
Compression/ejection force
18. • Tooling: The shape, size and concavity of the tooling should
be examined.
• Compression speed and force: compression speed of the
tablet press is adjusted based on the flow rate of the
granulation, tablet weight required and tablet hardness
required.
• TABLET COMPRESSION MACHINE
• a.How many compression stations does the compressor
have?
• b. What is the operating range (rpm) of the unit?
• c. What is the output range of the compressor (e.g., tablets
per min)? Will the unit meet the demands (sales forecast)
19. •d. What kind of powder feeding capabilities does the
equipment have (e.g., gravity, power-assisted, or centrifugal)?
Can this capability be altered or controlled (e.g., open feed
frame, forced below feeder)?
• e. What is the compression force range of the equipment? f.
Is the equipment capable of monitoring compression and
ejection force? g. Does the unit have precompression
capabilities? h. How long can the equipment operate without
routine maintenance?
